Jacob Leander
Overview
Explore the profile of Jacob Leander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hegelund Myrback T, Prothon S, Edman K, Leander J, Hashemi M, Dearman M, et al.
Lancet Rheumatol
. 2024 Jan;
2(1):e31-e41.
PMID: 38258274
Background: Glucocorticoids are highly effective and widely used anti-inflammatory drugs, but their use is limited by serious side-effects, including glucocorticoid-induced hyperglycaemia and diabetes. AZD9567 is a non-steroidal, selective glucocorticoid receptor...
2.
Leander J, Jirstrand M, Eriksson U, Palmer R
CPT Pharmacometrics Syst Pharmacol
. 2021 Nov;
11(2):212-224.
PMID: 34797036
Home-based measures of lung function, inflammation, symptoms, and medication use are frequently collected in respiratory clinical trials. However, new statistical approaches are needed to make better use of the information...
3.
Leander J, Sunnaker M, Rekic D, Aksenov S, Eriksson U, Johansson S, et al.
J Pharmacokinet Pharmacodyn
. 2021 Mar;
48(4):525-541.
PMID: 33728547
Verinurad, a uric acid transporter 1 (URAT1) inhibitor, lowers serum uric acid by promoting its urinary excretion. Co-administration with a xanthine oxidase inhibitor (XOI) to simultaneously reduce uric acid production...
4.
Rekic D, Johansson S, Leander J
Clin Pharmacokinet
. 2020 Sep;
60(3):319-328.
PMID: 32951150
Background And Objective: Febuxostat is a xanthine oxidase inhibitor indicated for gout and hyperuricemia. This work investigates potential clinically relevant covariates for febuxostat pharmacokinetics with a special focus on Asian...
5.
Almquist J, Sadiq M, Eriksson U, Hegelund Myrback T, Prothon S, Leander J
CPT Pharmacometrics Syst Pharmacol
. 2020 Jun;
9(8):444-455.
PMID: 32501650
AZD9567 is a potent and selective nonsteroidal oral glucocorticoid receptor modulator. It is developed as an anti-inflammatory drug with improved safety profile compared with steroids like prednisolone. Throughout the clinical...
6.
Olafsdottir H, Leander J, Almquist J, Jirstrand M
AAPS J
. 2018 Aug;
20(5):88.
PMID: 30069613
Nonlinear mixed effects (NLME) modeling based on stochastic differential equations (SDEs) have evolved into a promising approach for analysis of PK/PD data. SDE-NLME models go beyond the realm of standard...
7.
Almquist J, Leander J, Jirstrand M
J Pharmacokinet Pharmacodyn
. 2015 Mar;
42(3):191-209.
PMID: 25801663
The first order conditional estimation (FOCE) method is still one of the parameter estimation workhorses for nonlinear mixed effects (NLME) modeling used in population pharmacokinetics and pharmacodynamics. However, because this...
8.
Leander J, Almquist J, Ahlstrom C, Gabrielsson J, Jirstrand M
AAPS J
. 2015 Feb;
17(3):586-96.
PMID: 25693487
Inclusion of stochastic differential equations in mixed effects models provides means to quantify and distinguish three sources of variability in data. In addition to the two commonly encountered sources, measurement...
9.
Tapani S, Almquist J, Leander J, Ahlstrom C, Peletier L, Jirstrand M, et al.
J Pharm Sci
. 2014 Jul;
103(8):2571-84.
PMID: 24986056
Data were pooled from several studies on nicotinic acid (NiAc) intervention of fatty acid turnover in normal Sprague-Dawley and obese Zucker rats in order to perform a joint PKPD of...
10.
Leander J, Lundh T, Jirstrand M
Math Biosci
. 2014 Mar;
251:54-62.
PMID: 24631177
In this paper we consider the problem of estimating parameters in ordinary differential equations given discrete time experimental data. The impact of going from an ordinary to a stochastic differential...